{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:20:30Z","timestamp":1789849230780,"version":"4.0.1"},"publisher-location":"Cham","reference-count":23,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319403182","type":"print"},{"value":"9783319403205","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-3-319-40320-5_1","type":"book-chapter","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T12:01:09Z","timestamp":1475323269000},"page":"3-12","source":"Crossref","is-referenced-by-count":58,"title":["MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology"],"prefix":"10.1007","author":[{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"issue":"24","key":"1_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR (1980) Smoldering multiple myeloma. N Engl J Med 302(24):1347\u20131349. doi: 10.1056\/NEJM198006123022405","journal-title":"N Engl J Med"},{"issue":"12","key":"1_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013548. doi: 10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"18","key":"1_CR3","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1056\/NEJMc1310911#SA1","volume":"369","author":"SY Kristinsson","year":"2013","unstructured":"Kristinsson SY, Holmberg E, Blimark C (2013) Treatment for high-risk smoldering myeloma. N Engl J Med 369(18):1762\u20131763. doi: 10.1056\/NEJMc1310911#SA1","journal-title":"N Engl J Med"},{"issue":"5","key":"1_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","volume":"28","author":"RA Kyle","year":"2014","unstructured":"Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV (2014) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 28(5):775\u2013790. doi: 10.1016\/j.hoc.2014.06.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"1_CR5","doi-asserted-by":"publisher","unstructured":"Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA (2010) Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28(4):690\u2013697. doi:JCO.2009.22.2257 [pii] 10.1200\/JCO.2009.22.2257 [doi]","DOI":"10.1200\/JCO.2009.22.2257"},{"issue":"18","key":"1_CR6","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","volume":"117","author":"M Dimopoulos","year":"2011","unstructured":"Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S (2011) Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 117(18):4701\u20134705. doi: 10.1182\/blood-2010-10-299529","journal-title":"Blood"},{"issue":"9","key":"1_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9):1606\u20131610. doi: 10.1200\/JCO.2009.25.5356","journal-title":"J Clin Oncol"},{"issue":"12","key":"1_CR8","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/leu.2014.230","volume":"28","author":"E Kastritis","year":"2014","unstructured":"Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA (2014) The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28(12):2402\u20132403. doi: 10.1038\/leu.2014.230","journal-title":"Leukemia"},{"issue":"5","key":"1_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","volume":"365","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Larson D, Kyle RA (2011) Diagnosis of smoldering multiple myeloma. N Engl J Med 365(5):474\u2013475. doi: 10.1056\/NEJMc1106428","journal-title":"N Engl J Med"},{"key":"1_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.313","author":"AJ Waxman","year":"2014","unstructured":"Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM (2014) Classifying ultra-high risk smoldering myeloma. Leukemia. doi: 10.1038\/leu.2014.313","journal-title":"Leukemia"},{"issue":"4","key":"1_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2012.296","volume":"27","author":"JT Larsen","year":"2013","unstructured":"Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV (2013) Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27(4):941\u2013946. doi: 10.1038\/leu.2012.296","journal-title":"Leukemia"},{"issue":"4","key":"1_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2012.309","volume":"27","author":"E Kastritis","year":"2013","unstructured":"Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA (2013) Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27(4):947\u2013953. doi: 10.1038\/leu.2012.309","journal-title":"Leukemia"},{"issue":"6","key":"1_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24(6):1121\u20131127. doi: 10.1038\/leu.2010.60","journal-title":"Leukemia"},{"key":"1_CR14","doi-asserted-by":"publisher","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ, 3rd, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582\u20132590. doi:356\/25\/2582 [pii] 10.1056\/NEJMoa070389 [doi]","DOI":"10.1056\/NEJMoa070389"},{"issue":"5","key":"1_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, Rosinol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, Lopez J, Olavarria E, Quintana N, Garcia JL, Blade J, Lahuerta JJ, San Miguel JF (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369(5):438\u2013447. doi: 10.1056\/NEJMoa1300439","journal-title":"N Engl J Med"},{"issue":"21","key":"1_CR16","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood.V124.21.3465.3465","volume":"124","author":"M-V Mateos","year":"2014","unstructured":"Mateos M-V, Hernandez MT, Giraldo P, De La Rubia J, de Arriba F, L\u00f3pez-Corral L, Rosi\u00f1ol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, L\u00f3pez J, Olavarr\u00eda E, Quintana N, Garc\u00eda JL, Blade J, Lahuerta JJ, San Miguel JF (2014) Long term follow-up on the tretament of high risk smoldering myeloma with lenalidomide plus low dose Dex (Rd) (phase III spanish trial): persistent benefit in overall survival. Blood 124(21):3465\u20133465","journal-title":"Blood"},{"key":"1_CR17","doi-asserted-by":"publisher","unstructured":"Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las Heras N, de Coca AG, Hernandez JM, Galende J, Martin-Nunez G, Barez A, Alonso JM, Martin A, Lopez-Berges C, Orfao A, San Miguel JF, Vidriales MB (2010) Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 148(1):110\u2013114. doi:BJH7929 [pii] 10.1111\/j.1365-2141.2009.07929.x [doi]","DOI":"10.1111\/j.1365-2141.2009.07929.x"},{"issue":"34","key":"1_CR18","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1200\/jco.2012.48.4923","volume":"31","author":"K Neben","year":"2013","unstructured":"Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31(34):4325\u20134332. doi: 10.1200\/jco.2012.48.4923","journal-title":"J Clin Oncol"},{"issue":"1","key":"1_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","volume":"123","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78\u201385. doi: 10.1182\/blood-2013-07-515239","journal-title":"Blood"},{"issue":"21","key":"1_CR20","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V124.21.3379.3379","volume":"124","author":"T Muta","year":"2014","unstructured":"Muta T, Iida S, Matsue K, Sunami K, Isoda J, Harada N, Saburi Y, Okamura S, Kumagae K, Watanabe J, Kuroda J, Aoki K, Ogawa R, Miyamoto T, Akashi K, Takamatsu Y (2014) Predictive significance of serum beta 2-microglobulin levels and M-protein velocity for symptomatic progression of smoldering multiple myeloma. Blood 124(21):3379\u20133379","journal-title":"Blood"},{"issue":"21","key":"1_CR21","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V124.21.2071.2071","volume":"124","author":"R Hajek","year":"2014","unstructured":"Hajek R, Sandecka V, Seckinger A, Spicka I, Scudla V, Gregora E, Radocha J, Brozova L, Jarkovsky J, Rihova L, Mikulasova A, Starostka D, Walterova L, Adamova D, Kessler P, Brejcha M, Vonke I, Obernauerova J, Valentova K, Adam Z, Minarik J, Straub J, Gumulec J, Ho AD, Hillengass J, Goldschmidt H, Maisnar V, Hose D (2014) Prediction of progression of smouldering into therapy requiring multiple myeloma by easily accessible clinical factors [in 527 Patients]. Blood 124(21):2071\u20132071","journal-title":"Blood"},{"issue":"21","key":"1_CR22","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1182\/blood.V124.21.3363.3363","volume":"124","author":"C Fern\u00e1ndez de Larrea","year":"2014","unstructured":"Fern\u00e1ndez de Larrea C, Isola I, Cibeira MT, Rosi\u00f1ol L, Calvo X, Tovar N, Elena M, Magnano L, Ar\u00f3stegui JI, Rozman M, Yag\u00fce J, Blad\u00e9 J (2014) Smoldering multiple myeloma: impact of the evolving pattern on early progression. Blood 124(21):3363\u20133363","journal-title":"Blood"},{"key":"1_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0174-1","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, San Miguel JF (2013) New approaches to smoldering myeloma. Curr Hematol Malig Rep. doi: 10.1007\/s11899-013-0174-1","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Cancer Treatment and Research","Plasma Cell Dyscrasias"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-40320-5_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T06:44:35Z","timestamp":1601102675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-40320-5_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319403182","9783319403205"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-40320-5_1","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}